Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
IKT

IKT - Inhibikase Therapeutics Inc Stock Price, Fair Value and News

$2.01+0.02 (+1.01%)
Market Closed

35/100

IKT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

35/100

IKT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

IKT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IKT Price Action

Last 7 days

6.9%

Last 30 days

17.5%

Last 90 days

30.5%

Trailing 12 Months

-8.6%

IKT RSI Chart

IKT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IKT Valuation

Market Cap

151.1M

Price/Earnings (Trailing)

-3.17

Price/Sales (Trailing)

450.18

Price/Free Cashflow

-5.9

IKT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

IKT Fundamentals

IKT Revenue

Revenue (TTM)

260.5K

IKT Earnings

Earnings (TTM)

-47.7M

Earnings Growth (Yr)

-106.48%

Earnings Growth (Qtr)

-20.32%

IKT Profitability

Return on Equity

-65.37%

Return on Assets

-59.87%

Free Cashflow Yield

-16.96%

IKT Investor Care

Shares Dilution (1Y)

11.88%

Diluted EPS (TTM)

0.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20240000
2023141.9K251.8K324.1K260.5K
20222.4M1.6M867.7K123.4K
20211.8M3.0M3.3M3.1M
20201.0M910.6K804.5K698.5K
20190001.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Inhibikase Therapeutics Inc

IKT
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
 CEO
 WEBSITEinhibikase.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES6

Inhibikase Therapeutics Inc Frequently Asked Questions

IKT is the stock ticker symbol of Inhibikase Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Inhibikase Therapeutics Inc is 151.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, IKT's PE ratio (Price to Earnings) is -3.17 and Price to Sales (PS) ratio is 450.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IKT PE ratio will change depending on the future growth rate expectations of investors.